Clinical Trials Browser

Phase 1 × Melanoma × AZD 6244 × Clear all

NCT01364051 2026-03-18

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Phase 1 Active not recruiting

Melanoma

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT02768766 2023-08-31

Intermittent Selumetinib for Uveal Melanoma

Phase 1 Completed

Uveal Melanoma, Melanoma

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Phase 1 Completed

BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT00710515 2014-08-13

Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies

Phase 1 Completed

Melanoma